Evidence map›Paper›PMID 25624718›Full record

ArticleWorld journal of gastroenterology2015

Antiproliferative effects of cinobufacini on human hepatocellular carcinoma HepG2 cells detected by atomic force microscopy.

Qing Wu, Wei-Dong Lin, Guan-Qun Liao, Li-Guo Zhang, Shun-Qian Wen, Jia-Ying Lin

Abstract read
In one paragraph

Article in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Qing WuQing Wu, Wei-Dong Lin, Guan-Qun Liao, Li-Guo Zhang, Shun-Qian Wen, Jia-Ying Lin, Department of General Surgery, the Affiliated Foshan Hospital of Southern Medical University, Foshan 528000, Guangdong Province, China.
Wei-Dong LinQing Wu, Wei-Dong Lin, Guan-Qun Liao, Li-Guo Zhang, Shun-Qian Wen, Jia-Ying Lin, Department of General Surgery, the Affiliated Foshan Hospital of Southern Medical University, Foshan 528000, Guangdong Province, China.
Guan-Qun LiaoQing Wu, Wei-Dong Lin, Guan-Qun Liao, Li-Guo Zhang, Shun-Qian Wen, Jia-Ying Lin, Department of General Surgery, the Affiliated Foshan Hospital of Southern Medical University, Foshan 528000, Guangdong Province, China.
Li-Guo ZhangQing Wu, Wei-Dong Lin, Guan-Qun Liao, Li-Guo Zhang, Shun-Qian Wen, Jia-Ying Lin, Department of General Surgery, the Affiliated Foshan Hospital of Southern Medical University, Foshan 528000, Guangdong Province, China.
Shun-Qian WenQing Wu, Wei-Dong Lin, Guan-Qun Liao, Li-Guo Zhang, Shun-Qian Wen, Jia-Ying Lin, Department of General Surgery, the Affiliated Foshan Hospital of Southern Medical University, Foshan 528000, Guangdong Province, China.
Jia-Ying LinQing Wu, Wei-Dong Lin, Guan-Qun Liao, Li-Guo Zhang, Shun-Qian Wen, Jia-Ying Lin, Department of General Surgery, the Affiliated Foshan Hospital of Southern Medical University, Foshan 528000, Guangdong Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the antiproliferative activity of cinobufacini on human hepatocellular carcinoma HepG2 cells and the possible mechanism of its action.

methodsHepG2 cells were treated with different concentrations of cinobufacini. Cell viability was measured by methylthiazolyl tetrazolium (MTT) assay. Cell cycle distribution was analyzed by flow cytometry (FCM). Cytoskeletal and nuclear alterations were observed by fluorescein isothiocyanate-phalloidin and DAPI staining under a laser scanning confocal microscope. Changes in morphology and ultrastructure of cells were detected by atomic force microscopy (AFM) at the nanoscale level.

resultsMTT assay indicated that cinobufacini significantly inhibited the viability of HepG2 cells in a dose-dependent manner. With the concentration of cinobufacini increasing from 0 to 0.10 mg/mL, the cell viability decreased from 74.9% ± 2.7% to 49.41% ± 2.2% and 39.24% ± 2.1% (P < 0.05). FCM analysis demonstrated cell cycle arrest at S phase induced by cinobufacini. The immunofluorescence studies of cytoskeletal and nuclear morphology showed that after cinobufacini treatment, the regular reorganization of actin filaments in HepG2 cells become chaotic, while the nuclei were not damaged seriously. Additionally, high-resolution AFM imaging revealed that cell morphology and ultrastructure changed a lot after treatment with cinobufacini. It appeared as significant shrinkage and deep pores in the cell membrane, with larger particles and a rougher cell surface.

conclusionCinobufacini inhibits the viability of HepG2 cells via cytoskeletal destruction and cell membrane toxicity.

Indexed as

Microscopy, Atomic ForceActin CytoskeletonAmphibian VenomsAntineoplastic AgentsCarcinoma, HepatocellularCell NucleusCell ProliferationCell ShapeCell SurvivalDose-Response Relationship, DrugFlow CytometryHep G2 CellsHumansLiver NeoplasmsMicroscopy, ConfocalS Phase Cell Cycle CheckpointsAmphibian VenomsAntineoplastic AgentshuachansuAtomic force microscopyCell viabilityCinobufaciniHepatocarcinomaHepG2 cells

Identifiers

PMID25624718
PMCPMC4299337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.